Stocks News

LAST PRICE
162.6400
TODAY'S CHANGE (%)
Trending Up1.1200 (0.6934%)

Bid / Lots
161.6000/ 1
Ask / Lots
162.0000/ 1
Open / Previous Close
161.2700 / 161.5200
Day Range
Low 159.6900
High 163.0500
52 Week Range
Low 130.9601
High 182.8900
Volume
5,483,844
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- DJ AbbVie Is Maintained at Overweight by Barclays, from 11:36AM ET on Monday Apr 29, 2024 by Dow Jones
  11:36AM ET on Monday Apr 29, 2024 by Dow Jones
  Companies Mentioned: ABBV
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ABBV/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 29, 2024 11:36 ET (15:36 GMT)
- BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating, from 11:24AM ET on Monday Apr 29, 2024 by MT Newswires
  11:24AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: ABBV
  11:24 AM EDT, 04/29/2024 (MT Newswires) -- AbbVie (ABBV) has an average outperform rating and a price target range of $161 to $206, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major b...
- DJ AbbVie Is Maintained at Outperform by BMO Capital, from 10:19AM ET on Monday Apr 29, 2024 by Dow Jones
  10:19AM ET on Monday Apr 29, 2024 by Dow Jones
  Companies Mentioned: ABBV
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ABBV/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 29, 2024 10:19 ET (14:19 GMT)
- Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196, from 8:37AM ET on Monday Apr 29, 2024 by MT Newswires
  8:37AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: ABBV
  08:37 AM EDT, 04/29/2024 (MT Newswires) -- AbbVie (ABBV) has an average rating of outperform and price targets ranging from $161 to $206, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from m...
- Barclays Adjusts Price Target on AbbVie to $187 From $195, from 8:24AM ET on Monday Apr 29, 2024 by MT Newswires
  8:24AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: ABBV
  08:24 AM EDT, 04/29/2024 (MT Newswires) -- AbbVie (ABBV) has an average rating of outperform and price targets ranging from $161 to $206, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from m...

Today
- Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 3 hours ago by MT Newswires
  3 hours ago by MT Newswires
  Companies Mentioned: GSK, NVO, NVS, TEVA, AZN, AMPH
- Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: ETN, F, GSK, HSBC, HMC, KO, LLY, BBVA, MCD, MSFT, NVO, TSLA, TEVA, TM, GM, WMT, AZN, AMPH, CRVS
- Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: GSK, NVO, NVS, TEVA, AZN, AMPH
- FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: GSK, NVO, NVS, TEVA, AZN, AMPH
- --FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: GSK, NVO, TEVA, AZN, AMPH
Yesterday
- European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares, from 12:11PM ET on Monday Apr 29, 2024 by MT Newswires
  12:11PM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: META, AZN, SHEL, DB
- AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed, from 10:56AM ET on Monday Apr 29, 2024 by MT Newswires
  10:56AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: AIM, AZN
- AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement, from 10:26AM ET on Monday Apr 29, 2024 by MT Newswires
  10:26AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: AZN
- Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine, from 10:11AM ET on Monday Apr 29, 2024 by MT Newswires
  10:11AM ET on Monday Apr 29, 2024 by MT Newswires
  Companies Mentioned: MRK
- Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, from 9:00AM ET on Monday Apr 29, 2024 by Business Wire
  9:00AM ET on Monday Apr 29, 2024 by Business Wire
  Companies Mentioned: MRK

AbbVie Inc
NYSE:ABBVUnited States

Search Criteria

Yesterday

DJ AbbVie Is Maintained at Overweight by Barclays, from 11:36AM ET on Monday Apr 29, 2024 by Dow Jones

BMO Capital Cuts Price Target on AbbVie to $180 From $195, Maintains Outperform Rating, from 11:24AM ET on Monday Apr 29, 2024 by MT Newswires

DJ AbbVie Is Maintained at Outperform by BMO Capital, from 10:19AM ET on Monday Apr 29, 2024 by Dow Jones

Morgan Stanley Adjusts AbbVie's Price Target to $191 From $196, from 8:37AM ET on Monday Apr 29, 2024 by MT Newswires

Barclays Adjusts Price Target on AbbVie to $187 From $195, from 8:24AM ET on Monday Apr 29, 2024 by MT Newswires

Peers Headlines

Today

Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 3 hours ago by MT Newswires

Top Midday Stories: Shares of Eli Lilly, HSBC Get Post-Earnings Bump; BBVA Exploring Merger With Sabadell; FTC Disputes 300 'Junk' Patent Listings, from 7 hours ago by MT Newswires

Update: FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 7 hours ago by MT Newswires

FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 8 hours ago by MT Newswires

--FTC Challenging 'Junk' Patent Listings for Ozempic, Victoza, Other Medications, from 8 hours ago by MT Newswires

Yesterday

European Equities Close Mixed in Monday Trading; Economic Sentiment Falls in April; Lawsuit Dents Deutsche Bank Shares, from 12:11PM ET on Monday Apr 29, 2024 by MT Newswires

AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed, from 10:56AM ET on Monday Apr 29, 2024 by MT Newswires

AstraZeneca Says Enhertu Phase 3 Trial Shows 'Statistically Significant' Progression-Free Breast Cancer Survival Improvement, from 10:26AM ET on Monday Apr 29, 2024 by MT Newswires

Merck Reports Positive Data for Investigational 21-Valent Pneumococcal Vaccine, from 10:11AM ET on Monday Apr 29, 2024 by MT Newswires

Merck Announces Positive Data for V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, from 9:00AM ET on Monday Apr 29, 2024 by Business Wire